The ups and downs of pharmacopoeial harmonization
This article was originally published in Scrip
As drug regulation becomes more global in nature, international trade continues to expand, and drug substances are increasingly manufactured using biotechnology techniques, the European Pharmacopoeia Commission is taking steps to develop more harmonized international quality standards, and is also extending its reach to encompass the quality of finished products rather than just pharmaceutical substances.
You may also be interested in...
Companies marketing dexamethasone in Europe have been told they can use a CHMP endorsement to request the addition of COVID-19 to their product license.
A “powerful new vision” for the post-Brexit UK regulatory framework was unveiled at a conference organized by the BioIndustry Association and the medicines regulator, the MHRA.
InflaRx and Relief Therapeutics/NeuroRx are investigating potential new treatments for COVID-19-induced pneumonia and for coronavirus-related ARDS.